Despite this evidence, treatment of fever is common in the ICU setting and likely related to standard dogma rather than evidence-based practice. In this prospective controlled trial by Young et al. published in the NEJM on December 3, 2015, 700 ICU patients with fever of known or suspected infectious etiology were randomized to receive either 1 g of intravenous acetaminophen or placebo every 6 hours until ICU discharge, resolution of fever, cessation of antimicrobial therapy, or death (20). The patients in the treatment group did have a statistically, but likely not clinically, relevant lower mean daily average temperature (absolute difference −0.28 °C, P<0.001). Sustained resolution of fever was also significantly higher in the treatment versus placebo group (22.8% vs. 16.9%, P=0.05). The main outcome was ICU-free days until day 28, which was not shown to be decreased in the treatment arm. Secondary outcomes, including 28 and 90-day mortality and ICU and hospital length of stay, were also not significantly different between groups. However, acetaminophen was associated with a shorter ICU stay than placebo among survivors and a longer stay in non-survivors. In terms of adverse events, there was no difference between groups in discontinuation of the drug due to liver dysfunction, and one patient in the placebo group suffered from markedly elevated temperature associated with death. It should be noted that the study population was predominantly non-surgical and that the treatment period was relatively short. More and more high-level randomized controlled trials are supporting the “let it ride” philosophy compared to the original prospective observational studies, which seem to support the opposite.